Introduction
============

Clomiphene citrate (CC) is used for the induction of ovulation or growth of multiple follicles in the treatment of infertility. It binds to estrogen receptors in the hypothalamus and this binding causes an anti-estrogenic effect. By a negative feedback mechanism, CC stimulates the gonadotropin-releasing hormone pulse and induces gonadotropin secretion from the anterior pituitary gland \[[@B1][@B2]\].

CC is considered to be an inexpensive, effective, and safe drug for ovulation induction. For these reasons, it is widely used as a first-line treatment for anovulatory and unexplained infertility. CC induces ovulation in approximately 70% to 85% of patients, but the pregnancy rate is lower than the ovulation rate. This may be due to the anti-estrogenic effects of CC on endometrial growth and cervical mucus production, a decrease in uterine blood flow, impaired synthesis of placental protein 14, subclinical pregnancy loss, impaired tubal transport, and detrimental effects on oocytes \[[@B3]\]. Of these, decreased endometrial development is a major undesired effect \[[@B4][@B5][@B6]\]. In fact, endometrial thickness is significantly thinner in women taking CC than in women not taking CC \[[@B4][@B5][@B6]\]. Satirapod et al. \[[@B7]\] reported an endometrial thickness of around 9.04 mm in women taking CC, while endometrial thickness in a natural cycle group was about 9.52 mm on the day of ovulation. Thus, overcoming the anti-estrogenic effect of CC on endometrial growth is important for achieving pregnancy in CC-assisted cycles. The anti-estrogenic effect of CC is exerted in a dose-dependent manner and continues until the late follicular phase in the standard CC treatment cycle. Therefore, using different doses and a short duration of CC treatment might be a solution for improving endometrial growth during the CC cycle.

In this study, we compared endometrial growth and pregnancy rates between two different protocols: 150 mg CC for three days and 100 mg CC for five days, with additional gonadotropins, in a time intercourse cycle in polycystic ovary syndrome (PCOS) patients.

Methods
=======

This study was a retrospective pilot study conducted by a university and a private infertility clinic. A total of 114 women aged less than 40 years were included in the study from January 2013 to March 2014. Patients conducting timed intercourse, but not intrauterine sperm injection (IUI), were collected consecutively without omission. The inclusion criteria for the patients were as follows: (1) a basal follicle-stimulating hormone (FSH) level of less than 10 mIU/mL, (2) normal hysterosalpingography (HSG) findings, (3) an adequate number of sperm for timed insemination, and (4) a PCOS diagnosis identified by the 2003 European Society for Human Reproduction/American Society of Reproductive Medicine (ESHRE/ASRM, Rotterdam) criteria.

The patients in this study were non-smokers and did not have any major medical illness including hypertension. Patients were excluded if they had myoma, adenomyosis, a congenital uterine anomaly, or ovarian tumors. Patients were also excluded if they used estrogens, progesterone, androgens, or had a history of chronic use of any medication within the previous three months, including non-steroidal anti-inflammatory agents. None of the patients showed abnormal findings in the uterine cavity on HSG.

Patients were divided into two groups and treated in accordance with the controlled ovarian stimulation (COS) protocol. In group A, 104 COS cycles in 67 patients were included. In each cycle, 150 mg CC (Clomid, Young Poong Corp., Seoul, Korea) was given for three consecutive days starting on the third day of the cycle. In group B, 69 COS cycles in 47 patients were included. 100 mg CC was given for five consecutive days starting on the third day of the cycle. In both groups, additional human menopausal gonadotropin (hMG) Menopur (Ferring Pharmaceuticals, Kiel, Germany) was administered every other day; patients weighing more than 60 kg received 225 IU hMG per dose and those weighing below 60 kg received 150 IU hMG. hMG administration started on day 7 and continued until human chorionic gonadotropin (hCG) administration, after which the dose of hMG was adjusted according to ovarian response. Endometrial thickness and follicular growth were assessed by vaginal ultrasonography (Voluson S8-5451540, Voluson E8C vaginal transducer, GE Healthcare, Waukesha, WI, USA).

In cases of premature luteinizing hormone (LH) surge or no response, the cycle was cancelled. Premature LH surge was diagnosed by several ultrasonographic characteristics, such as the appearance of a corpus luteum, the disappearance of the triple line of endometrium, and fluid collection at the cul-de-sac. If there was no follicular growth after the fifteenth day of the cycle and no increase in follicular diameter at two separate follow-up ultrasonographic examinations, then there was a diagnosis of \'no response\'.

When follicles reached a diameter of 18 mm as measured by ultrasonography, 500 µg chorionic gonadotropin alpha (Ovidrel Pen, Merck Serono, Darmstadt, Germany) was administered to induce ovulation. After a longitudinal view of the uterus was obtained, the thickness of the endometrium was measured at the maximum distance between each endometrial-myometrial interface on the day of hCG administration. The number of follicles on the day of hCG administration was also assessed by vaginal ultrasonography. Timed intercourse was recommended at 24 and 48 hours after hCG injection.

1. Statistical analysis
-----------------------

Statistical analysis was carried out with PASW ver. 18.0 (SPSS Inc., Chicago, IL, USA). The Mann-Whitney U test with Bonferroni correction, Fisher\'s test, and Kruskal-Wallis H test were employed as appropriate. Differences were considered to be significant if the *p*-value was less than 0.05. Data were expressed as mean±standard deviation.

Results
=======

[Table 1](#T1){ref-type="table"} presents the patients\' characteristics. There was no significant difference between the two groups in the age of patients, duration of infertility, or basal hormone levels including FSH, LH, free testosterone, estradiol, prolactin, dehydroepiandrosterone-sulfate, and thyroid stimulating hormone. Body mass index (BMI) was not significantly different between groups.

COS outcomes can be ascertained from [Table 2](#T2){ref-type="table"}. Two patients in group A showed a premature LH surge and did not follow the timed intercourse cycle. Three other patients had no response until menstrual cycle day 20, 22, and 23, respectively, and these cycles were also cancelled. In group B, no premature LH surge was observed; however, three cycles were cancelled because of a poor response. None of the cancelled cycles were included in the final statistical analysis.

The number of additional hMG doses was not significantly different between the two groups. The number of days of hCG administration and mature follicle counts on the day of hCG administration were similar between both groups. The endometrial thickness on the day of hCG administration was significantly different between the two groups; the endometrial thickness in group A was greater than that in group B. The proportion of patients with a thin endometrium (\<7 mm) on the day of hCG administration was not significantly different between groups.

Clinical outcomes can be ascertained from [Table 3](#T3){ref-type="table"}. The pregnancy rate was significantly higher in group A. The multiple pregnancy rate was similar in both groups. One case of triplet pregnancy was observed in group A; all other multiple pregnancies were twin pregnancies. The abortion rate was similar in both groups. Five cases of mild ovarian hyperstimulation syndrome (OHSS) developed.

Discussion
==========

It is well known that endometrial growth is one of the most important factors in implantation. Esmailzadeh and Faramarzi \[[@B8]\] reported that endometrial thickness on the day of hCG administration was significantly greater in CC-IUI cycles in which pregnancy was achieved. Furthermore, according to El-Toukhy et al. \[[@B9]\], the lowest pregnancy rates are associated with endometrial thicknesses of \<7 mm or \>14 mm in frozen-thawed embryo replacement cycles.

Dehbashi et al. \[[@B4]\] reported that endometrial thickness was significantly thinner in women taking CC than in a control group during the late proliferative phase. These authors suggested several methods to overcome the problem of a thin endometrium after the use of CC, such as the use of phytoestrogens, transdermal estrogen, or an aromatase inhibitor.

Unfer et al. \[[@B10]\] reported the effectiveness of CC in ovulation induction, either alone or combined with phytoestrogens, in patients receiving intrauterine insemination, stating that a high dose of phytoestrogens might reverse the deleterious effects of CC on endometrial thickness. However, safety data and proper protocols for the use of phytoestrogens have not yet been established, and there is a risk that these substances may increase the risk of endometrial hyperplasia.

Transdermal estrogen is also used for endometrial growth in CC treatment cycles \[[@B11]\]. Shimoya et al. \[[@B11]\] reported that endometrial thickness was significantly thicker in patients receiving CC and transdermal estrogen, but did not report the pregnancy rate. There is a risk that administration of additional estrogen might affect LH levels and cause an LH surge at an earlier stage or induce a higher progesterone level.

Recently, aromatase inhibitors have been widely used for ovulation induction in patients with anovulatory or unexplained infertility. Because aromatase inhibitors do not deplete estrogen receptors in central and peripheral target tissues, they may have no negative impact on endometrium \[[@B12]\]. Barroso et al. \[[@B13]\] reported that a significantly thicker endometrium was observed in patients who received letrozole than in patients who received CC (9.5±1.5 mm vs. 7.3±1.1 mm, *p*\<0.001). However, aromatase inhibitors are relatively expensive and there are still some safety issues with their use \[[@B14]\].

Takasaki et al. \[[@B14]\] conducted a prospective randomized controlled study to examine the effect of either reduced-dose or early administration of CC in patients with a thin endometrium compared with standard CC treatment. They reported that the endometrium was thicker in the two experimental groups than in the standard group. CC is cleared through the liver and excreted in the stool, and approximately 85% is eliminated within a week \[[@B15]\]. In this study, we used a protocol of early discontinuation of CC. We found that the endometrium was thicker and the pregnancy rate was higher in the early discontinuation group, while the number of follicles larger than 16 mm in diameter was not different.

There are some limitations to this study. First, the number of patients included in the study was relatively small and treatment was not randomized. Also, there were differences in the number of patients enrolled in each group that arose in the process of selecting patients according to the criteria of each group. Second, this study included only PCOS patients, who are supposed to be high responders to the treatment used, and the dose of CC was relatively high. Moreover, the BMI of the patients in this study was relatively low, since lower BMI is one of the features of Korean PCOS patients \[[@B16]\]. These factors might affect pregnancy rates and might be responsible for side effects of PCOS such as OHSS, which was observed in three cases in group A and two cases in group B, and multiple pregnancy rates, which were 18.4% in group A and 20.0% in group B. However, adjusting the hMG dose can control these complications and reduce the cost of COS. Finally, we did not check the effects of CC on the characteristics of the cervical mucus.

This study is a preliminary trial for a new CC regimen aimed at overcoming the anti-estrogenic effects of CC on the endometrium. Patients with a higher dose and shorter duration of CC showed an increased endometrial thickness and higher pregnancy rate. Further investigation should be performed in large populations, including comparison with patients from other countries and using proper randomization to determine the adequate dose and timing of CC, as well as the appropriate dose of hMG, in infertile patients.
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###### Patient characteristics
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Values are presented as mean±standard deviation.

FSH, follicle-stimulating hormone; LH, luteinizing hormone; DHEA-S, dehydroepiandrosterone-sulfate; TSH, thyroid stimulating hormone.

###### COS outcomes and endometrial thickness in patients receiving three- or five-day treatment

![](cerm-42-106-i002)

Values are presented as mean±standard deviation.

COS, controlled ovarian stimulation; LH, luteinizing hormone; hCG, human chorionic gonadotropin; hMG, human menopausal gonadotropin.

^a)^104 COS cycles in 67 patients; ^b)^69 COS cycles in 47 patients.

###### Clinical outcomes in patients with successful ovulation induction
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Values are presented as percent (number).

[^1]: ^\*^The first two authors contributed equally to this work.
